Clinical Medicine Reviews in Therapeutics 2010:2
Review
Published on 15 Jun 2010
DOI: 10.4137/CMRT.S5090
Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics
Acute lymphoblastic leukaemia (ALL) is the most common leukaemia in children and third most common in adults. Although the majority of children and adults with ALL achieve a complete remission with intensive chemotherapy, relapse will occur in 20% and 50% respectively. As further intensification risks greater toxicity and may not diminish the risk of relapse, new targeted therapies with less overall toxicity are urgently needed. There have been a number of new agents recently developed directed at specific cellular pathways involved in leukaemia genesis and are beginning to make their way into early phase clinical trials. This review will highlight a number of these novel chemotherapy agents and the pathways they target in relapse ALL.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Facebook Twitter
Pinterest